Neothermia Corp's en-bloc Breast Biopsy System Receives Expanded Indications for Tissue Excision
7th Sep 2005, 16:35 GMT
Neothermia Corp, an emerging leader in the development and marketing of minimally invasive systems for the diagnosis of breast cancer, has received US FDA 510 clearance for expanded indications of its en- bloc breast Biopsy System for complete or partial removal of an imaged abnormality for histological review.
Latest news from Radiology News from myHealthcareNews.com:
- Genzyme increasing R&D presence in San Antonio area
- Eisai Breaks Ground for New Oncology Facility in Research Triangle Park
- Ashok Gupta, MD Joins the Physician Team at Desert Radiologists
- AMICAS Offers Free PACS Webinar for RSNA Attendees
- Enrollment Completed Utilizing Cytori's Adipose-Derived Stem Cell Technology for Treatment of Breast Cancer Complications
- Groundbreaking for Cancer Center on Premier Healh Campus - Middletown
- BSD Medical Sends Message of Hope at Largest Conference of US Radiation Oncologists
- Volcano to Offer 7.5M Shares
- Nautilus Biotech and Creabilis Therapeutics Achieve Technical Milestone in Collaboration to Improve HMGB1 Box A for the Treatment of Rage- and HMGB1-Related Pathologies.
- Adherex Reports Q3 2006 Financial Results